Gilde Healthcare company AM-Pharma announces positive clinical data from Phase 1b study evaluating ilofotase alfa in hypophosphatasia patients
AM-Pharma B.V. today announced positive clinical results from the Phase 1b study evaluating the company’s proprietary recombinant alkaline phosphatase, ilofotase alfa, as potential enzyme replacement therapy in adult hypophosphatasia (HPP) patients. HPP is an inherited metabolic disease, characterized by low activity of tissue non-specific alkaline phosphatase (TNAP),...